AzTrials
AzTrials

Labor Fetal AnoxiaNCT03268486

Evaluation of a Novel Signal Acquisition Technique for Intrapartum Cardiotocography

An observational study of Labor Fetal Anoxia and Fetal Monitoring, run by University of Lisbon.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cardiotocography (CTG) is widely used during labour wards in industrialised countries and consists of fetal heart rate and uterine contraction monitoring. The main aim is to identify fetuses that are being poorly oxygenated during labour and require medical intervention to revert the situation or expedite delivery. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Labor Fetal Anoxia, Fetal Monitoring
How many people
50 participants
Where
No sites listed yet
Study dates
1 Oct 2017to 31 May 2019
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: All pregnant women in labour at Hospital de Santa Maria, Lisbon

Who may be able to join

  • Singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. Patients with risk factors for intrapartum hypoxia will also be included.

Who cannot join

  • Do not give a written consent.

Trial locations and contacts

No sites are listed yet.

Catarina Carvalho, Resident contact

+351919297913

catarinareiscarvalho@gmail.com

About this study

Cardiotocography (CTG) is widely used during labour wards in industrialised countries and consists of fetal heart rate and uterine contraction monitoring. The main aim is to identify fetuses that are being poorly oxygenated during labour and require medical intervention to revert the situation or expedite delivery.

The need for technical development of CTG is well-recognized, as some of the existing techniques are prone to signal loss and contamination from the maternal heart rate, while others are invasive and have established contra-indications. They also limit maternal mobilisation, contributing to maternal dissatisfaction, and possibly to adverse maternal and neonatal outcomes.

New techniques for CTG acquisition will shortly be made available by a leading technological company, providing non-invasive monitoring and allowing full maternal mobilisation, and with the potential to change the way labour is conducted in high-resource countries. There is a need for a systematic evaluation of their clinical performance and benefit.

Read the detailed description

First phase of the study will start in October 2017 in labor wards at Hospital de Santa Maria, Lisbon where performing continuous cardiotocographic fetal monitoring with conventional Doppler technology is the routine procedure. Through a collaboration with Phillips (Boeblingen, Germany) we will have access to a transabdominal ECG/EHG recorder that has high accuracy/reliability and Bluetooth technology providing mobility and and more comfort for mothers. This new device works through five disposable electrodes that are positioned on the maternal abdomen in a standardized manner: one electrode is placed near the umbilicus, a second is placed above the symphysis pubis in a vertical line from the umbilicus, a third and a fourth are placed on opposite sides of the abdomen horizontal to the umbilicus; the ground is placed on the upper right side. Women will be informed of the study by posters and leaflets distributed during the antenatal period and on arrival at labor wards. The inclusion criteria are singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. Patients with risk factors for intrapartum hypoxia will also be included. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible. The maternal abdominal skin will be prepared for low impedance by gentle excoriation of the surface skin cells. Monitoring will be maintained until as close to delivery as possible, and the three FHR signals will be conveyed to a computer acquisition storage system for offline analysis. We aim a sample size of 100 participants. EHG and TOCO will be compared for signal loss, contraction frequency, and contraction area. Transabdominal ECG and Doppler will be compared in terms of signal loss, and with internal ECG regarding signal accuracy. The signal quality will be analysed separately for each monitoring method for the time during which the FHR recorded. As the two FHR modalities do not share a common time clock, synchronisation should be achieved by cross correlating the two heart rate files and locating the peak correlation. The clinical management of labour will be uniquely on the basis of external Doppler ultrasound CTG recordings. Both signals will also be compared for coincidences with MHR determined by maternal ECG with FHR determined by internal ECG. The abdominal fECG monitor calculates the MHR as well as the FHR simultaneously. It uses the height and the width of the QRS complex, both of which are linked to the size of the heart, to differentiate between the fetal and maternal heart signals. Women will be encouraged to perform a sequence of standardized exercises, in the presence of the investigator, and the periods when the mother is lying down, sitting, standing and walking will be recorded.

A subgroup analysis will be performed in the different stages of labour, particularly during maternal pushing, as well as in women with different skin colour and body mass index categories and in the different positions they adopt. Both umbilical cord arterial and venous blood sampling will be performed for the diagnosis of newborn metabolic acidosis, as soon as possible after birth. Data on basic demographic characteristics, pregnancy complications, course of labor, and neonatal outcome will be obtained.

In the second phase of the study, we want to know if the different traces acquired from the same fetus through transabdominal ECG and Doppler CTG may have different interpretations and may lead to different obstetric attitudes. In order to do that we will retrospectively analyze all the independent traces through a computer analysis (Omniview-SisPorto program). This system emits visual and sound alerts when features associated with poor fetal oxygenation are detected and has been shown to provide analysis that is in good agreement with a consensus of experts. The main outcome will be the agreement of alerts displayed by each signal acquisition technique regarding the same fetus.

Keywords
Fetal monitoring, cardiotocography

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03268486
Study groupRoleWhat they receive
Triple monitoringPregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Signal quality

    Transabdominal ECG and Doppler will be compared in terms of signal loss, and with internal ECG regarding signal accuracy. The signal quality will be analysed separately for each monitoring method for the time during which the FHR recorded.

    Measured: The analysis will be made at the end of the recruiting phase (that will have 3 months of duration)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Aug 2017
  2. Study start1 Oct 2017 (estimated)
  3. Primary completion1 May 2018 (estimated)
  4. Study completion31 May 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
50 participants (estimated)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT03268486
Sponsor's protocol ID
ULisbon TAECG
Status last verified
Aug 2017
First submitted
29 Aug 2017
Last updated
31 Aug 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Labor Fetal Anoxia and Fetal Monitoring, run by University of Lisbon.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 31 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Catarina Carvalho, Resident (+351919297913, catarinareiscarvalho@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Signal quality (time frame: The analysis will be made at the end of the recruiting phase (that will have 3 months of duration)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in